An observational study in Osteoporosis, Postmenopausal, sponsored by 424 General Military Hospital. Completed at 1 site in Greece. Open to female participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by 424 General Military Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Osteoporosis, Postmenopausal with a site in Greece — 2 open to participants now, 3 under way, none of them phase 3. Osteoporosis, Postmenopausal · Greece.
Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, this one is the only one that started in 2019, is one of 7 observational ones, and was the 9th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →2 of the 14 studies in Osteoporosis, Postmenopausal with a site in Greece are open now. Recruiting first, the newest first:
National and Kapodistrian University of Athens · Sites in Greece
Women only
424 General Military Hospital · Sites in Greece, Italy
Ages 50–85 · Women only
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 20 Years to 85 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2019.
This study's enrollment of 220 is above the median of 160 across 57 observational studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 91 across the 7 interventional studies, 150 across the 7 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 7 most frequent:
424 General Military Hospital is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
424 General Military Hospital has 4 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoporosis, Postmenopausal with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06164795424 General Military HospitalSequential Therapies After Osteoanabolic Treatment | 2027-06-01 |
| NCT05575167424 General Military HospitalSingle or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Osteoporosis, Postmenopausal with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Circulating levels of several myokines will be measured in serum samples obtained from women in various categories of bone density and according to the presence of fracture or not as well as before and after treatment with teriparatide and denosumab
Serum samples for the measurement of several myokines will be obtained from: 1) equal groups of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis; 2) women with hip fracture compared with controls (women subjected to surgery due to knee osteoathritis); 3) women with osteoporosis treated with teriparatide or denosumab for 12 months
Substudy 1: equal groups (n=25) of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis Substudy 2: postmenopausal women with an incident hip fracture (n=40) compared with controls (postmenopausal women with knee osteoarhtritis) Substudy 3: postmenopausal women with osteoporosis will receive treatment with either teriparatide or denosumab for 12 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Substudy 1:
Substudy 2:
Substudy 3:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
Drug: Teriparatide
postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
Drug: Denosumab
1 subcutaneous injection daily for 12 months
Also known as: rhPTH 1-34
1 subcutaneous injection every 6 months for 12 months
Also known as: RANKL inhibitor
follistatin
circulating levels of myokine follistatin at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
activin-A
circulating levels of myokine activin-A at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
FSTL3
circulating levels of myokine FSTL3 at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
activin-B
circulating levels of activin-B at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
irisin
circulating levels of myokine irisin at baseline and their changes at 3 and 12 months with treatment
Time frame: 0,3,12 months
Plan to share: Undecided — Data will become available after study completion
Ran from Jun 2019 to primary completion in Sep 2020, 15 months.
Of 23 observational studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
424 General Military Hospital